Publication:

Efficacy and safety of hair serum containing Greyverse, EUK 134 and Amisol trio in premature greying of hair

Greying of hair, also known as achromotrichia or canities, is a part of ageing. Premature canities is a widespread, poorly characterised dermatological condition with little clinical and demographic information. We conducted this study to evaluate the efficacy and safety of hair serum containing Greyverse, EUK 134 and Amisol trio in premature greying of hair. Ten cases of premature canities (onset before 25 years of age) were recruited from the outpatient department at Cutis Academy of cutaneous sciences, Bengaluru. The participants were recruited after written informed consent from patients (>18 years age); whereas in patients <18 years age, it was provided by their parents/guardians. The Revgrey® hair serum formulation was asked to be applied twice daily for three months and its efficacy and safety was analyzed during follow-up at day 30 and 90. In our study, we found that the mean age of onset of greying was 14.9±4.33 years. The frontal region was the earliest affected area. The investigator’s assessment and patient’s self-assessment was recorded after completion of the treatment at 12 weeks. The investigator’s assessment revealed that 4 patients (0.4%) showed slightly increased recovery of hair while 3 patients (0.3%) showed moderately increased recovery of hair. The small sample size of the study was its limiting factor in arriving at a definite conclusion. We concluded that application of Revgrey® hair serum formulation in males and females suffering premature greying of hair is both safe and beneficial.